Feature | January 23, 2014

Study Finds No Significant Differences Between Commonly Used Carotid Stenting Systems in U.S.

Rates of death and stroke similarly low for three major systems

Carotid Stent Clinical Study Abbott Cordis National Cardiovascular Data Registry

Abbott Acculink Carotid Stent

January 23, 2014 — The three most common systems to place stents in blocked carotid arteries of the neck have similarly low rates of complication and death among U.S. patients, according to a study published by JACC: Cardiovascular Interventions.
 
“We found low rates of in-hospital death and stroke with carotid stenting regardless of the devices used on the order of 2 percent,” said lead author Jay Giri, M.D., M.P.H., assistant professor of clinical medicine at the University of Pennsylvania. “A tremendous amount of time and energy has been spent theorizing about various technical considerations of carotid stenting systems that might make one superior to another. Our study effectively argues that continued focus on these specific technical aspects is unlikely to significantly improve stroke and death rates around carotid stenting. The bottom line is that our finding should provide support for operators to use their judgment to select the stent most favorable for a particular anatomic or clinical situation.”
 
The study analyzed 12,135 consecutive carotid stent procedures in the National Cardiovascular Data Registry performed between January 2007 and March 2012. Penn researchers compared rates of in-hospital combined death/stroke among patients treated with Acculink/Accunet (Abbott), Xact/Emboshield (Abbott) and Precise/Angioguard (Cordis) stent/embolic protection device (EPD) combinations. The study found that in nearly 80 percent of cases examined, physicians paired stents with the corresponding EPD produced by the stent manufacturer. 
 
“In other types of non-carotid stenting, doctors often mix and match products from different companies,” Giri said. “With carotids, by and large, they don’t. They use companion stents and embolic protection devices from one company.”
 
Factors that may influence this pattern of use include that the U.S. Food and Drug Administration (FDA) approves carotid stenting systems as a unit of stent and EPD; operators may be more comfortable using an FDA-approved unit rather than “mixing and matching” stents with other EPDs; and reimbursement restrictions from Centers for Medicare & Medicaid Services (CMS).
 
The National Cardiovascular Data Registry supported this research by funding for statistical support.
 
For more information: www.upenn.edu

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init